G. Tomaras

M. Brown, M. Vincenti, G. Tomaras, 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections

Feng Gao, Bette Korber, Tongye Shen, 2011, PLoS pathogens.

Rectal and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge.

S. Hammer, M. McElrath, I. Frank, 2021, The Journal of clinical investigation.

Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge

S. Hammer, M. McElrath, I. Frank, 2021 .

Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates

D. Montefiori, D. Venzon, B. Keele, 2020, iScience.

Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines

J. Kublin, A. Fiore-Gartland, Xiaoying Shen, 2022, Frontiers in Immunology.

Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study

D. Montefiori, R. Gottardo, G. Pantaleo, 2022, Frontiers in Immunology.

Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost

S. Self, D. Montefiori, R. Gottardo, 2018, Journal of Virology.

High‐throughput quantitative analysis of HIV‐1 and SIV‐specific ADCC‐mediating antibody responses

J. Kappes, B. Haynes, J. Hoxie, 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation

Thomas B. Kepler, Christopher W. Woods, S. Munir Alam, 2014, Front. Immunol..

Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women.

J. Lambert, S. Gurunathan, G. Tomaras, 2005, The Journal of infectious diseases.

Initiation of immune tolerance–controlled HIV gp41 neutralizing B cell lineages

T. Kepler, H. Liao, B. Haynes, 2016, Science Translational Medicine.

Proceedings of the Frontiers of Retrovirology Conference 2016

R. König, D. Elleder, R. Sachidanandam, 2016, Retrovirology.

CD8+T-cell-mediated control of HIV-1 and SIV infection

G. Tomaras, K. Saunders, S. Freel, 2011, Immunologic research.

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

Jerome H. Kim, H. Liao, B. Haynes, 2013, Proceedings of the National Academy of Sciences.

Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study

S. McCormack, D. Montefiori, N. Frahm, 2016, PloS one.

A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates

Jennifer S. Wood, Muhammad Bilal Latif, A. Sette, 2021, Science Immunology.

Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.

Daniel E. Zak, Carrie D. Johnson, D. Zak, 2017, Blood advances.

Recombinant Simian Varicella Virus-Simian Immunodeficiency Virus Vaccine Induces T and B Cell Functions and Provides Partial Protection against Repeated Mucosal SIV Challenges in Rhesus Macaques

D. Montefiori, P. Marx, P. Kissinger, 2022, Viruses.

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

Allan C. deCamp, J. Kublin, D. Montefiori, 2020, PLoS medicine.

Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models

T. Hope, D. Montefiori, G. Ferrari, 2019, Journal of Virology.

Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control.

Kent J Weinhold, Terri Wrin, Guido Ferrari, 2003, The Journal of infectious diseases.

Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

Nico Pfeifer, Florian Klein, Michel C Nussenzweig, 2018, Nature Medicine.

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

J. Mascola, D. Montefiori, R. Bailer, 2017, PLoS medicine.

Novel directions in HIV-1 vaccines revealed from clinical trials.

N. Russell, G. Tomaras, J. Excler, 2013, Current opinion in HIV and AIDS.

HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers

J. Lambert, S. Gurunathan, G. Tomaras, 2006, AIDS.

3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates

B. Pulendran, B. Haynes, D. Montefiori, 2020, Science Immunology.

Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway

J. Kappes, D. Montefiori, L. Morris, 2019, Front. Immunol..

Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins

Q. Sattentau, John P. Moore, D. Montefiori, 2018, PLoS pathogens.

HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers

B. Haynes, William J. Faison, G. Ferrari, 2019, Scientific Reports.

T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response.

M. Ostrowski, M. Betts, M. Robb, 2017, JCI insight.

Human Epistatic Interaction Controls IL7R Splicing and Increases Multiple Sclerosis Risk

Edward M. Kennedy, Georgia D. Tomaras, Dennis C. Ko, 2017, Cell.

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

Karen G. Dowell, Jerome H. Kim, C. Bailey-Kellogg, 2016, Nature Medicine.

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)

M. McElrath, N. Russell, B. Graham, 2010, PloS one.

Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1

D. Douek, P. Gilbert, S. Rerks-Ngarm, 2021, eLife.

Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as the primary mechanism of vaccine-induced protection against HIV-1

D. Douek, P. Gilbert, S. Rerks-Ngarm, 2021, bioRxiv.

HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine

W. Borkowsky, M. McElrath, Y. Fong, 2017, Journal of Virology.

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

Jerome H. Kim, L. Jagodzinski, M. Robb, 2016, The Journal of infectious diseases.

HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition

D. Montefiori, R. Koup, D. Venzon, 2018, Nature Medicine.

Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates

Laura L. Sutherland, B. Haynes, D. Montefiori, 2021, PLoS pathogens.

Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses

H. Liao, B. Haynes, T. Hope, 2016, PLoS pathogens.

Vaccination with Vaxfectin® adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia

D. Montefiori, C. Labranche, C. Irene, 2013, Human vaccines & immunotherapeutics.

Tat-SF1 Is Not Required for Tat Transactivation but Does Regulate the Relative Levels of Unspliced and Spliced HIV-1 RNAs

Heather B. Miller, M. Garcia-Blanco, G. Tomaras, 2009, PloS one.

Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women

Vicki C. Ashley, S. Karim, L. Morris, 2016, AIDS.

Repeated semen exposure decreases cervicovaginal SIVmac251 infection in rhesus macaques

D. Weiner, L. Montaner, F. Kirchhoff, 2019, Nature Communications.

Control of Heterologous Simian Immunodeficiency Virus SIVsmE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques

N. Sardesai, D. Montefiori, Jishnu Das, 2018, Journal of Virology.

HIV-1 Negative Female Sex Workers Sustain High Cervical IFNε, Low Immune Activation and Low Expression of HIV-1 Required Host Genes

L. Montaner, K. Linn, Qingsheng Li, 2015, Mucosal Immunology.

Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates

B. Korber, H. Liao, Laura L. Sutherland, 2018, Journal of Virology.

Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.

Haiyan Chen, H. Liao, B. Haynes, 2015, The Journal of clinical investigation.

An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1.

T. Kepler, H. Liao, B. Haynes, 2014, The Journal of clinical investigation.

Vaccination establishes clonal relatives of germinal center T cells in the blood of humans

A. Aderem, M. McElrath, H. Robins, 2017, The Journal of experimental medicine.

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)

J. Fuchs, S. Kalams, N. Frahm, 2015, Open forum infectious diseases.

Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies

D. Irvine, D. Montefiori, Kelly K. Lee, 2022, Cell reports.

Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination

J. Kublin, G. Pantaleo, A. Fiore-Gartland, 2019, PloS one.

HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria.

K. Roskin, T. Kepler, H. Liao, 2014, Cell host & microbe.

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

S. Hammer, H. Liao, T. Hertz, 2016, The Journal of infectious diseases.

Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection

Mario Roederer, Bette Korber, Guido Ferrari, 2011, PLoS pathogens.

The immune response during acute HIV-1 infection: clues for vaccine development

Persephone Borrow, Andrew J. McMichael, Barton F. Haynes, 2009, Nature Reviews Immunology.

Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection.

F. Gao, R. Koup, D. Douek, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

Galit Alter, David C Montefiori, Nigel Garrett, 2018, The Lancet.

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

Lindsay N. Carpp, Allan C. deCamp, J. Mullins, 2022, Nature Medicine.

Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk.

Lindsay N. Carpp, J. Kublin, M. McElrath, 2022, The Journal of infectious diseases.

Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies

Allan C. deCamp, B. Haynes, D. Montefiori, 2021, Journal of virology.

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

Allan C. deCamp, Jerome H. Kim, D. Montefiori, 2017, The Journal of infectious diseases.

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants

J. Kublin, D. Montefiori, L. Morris, 2016, PloS one.

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap

D. Montefiori, L. Morris, C. Williamson, 2016, Clinical and Vaccine Immunology.

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

J. Kublin, D. Montefiori, H. Schuitemaker, 2020, The lancet. HIV.

Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens

S. Alam, A. Hill, S. Dennison, 2018, The Journal of Immunology.

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

Hyeong Mi Kim, D. Ho, L. Stamatatos, 2021, Science.

Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS.

W. Blattner, T. O'Brien, G. Tomaras, 2004, The Journal of infectious diseases.

HIV-1-specific antibody responses during acute and chronic HIV-1 infection

Georgia D Tomaras, B. Haynes, G. Tomaras, 2009, Current opinion in HIV and AIDS.

Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques

G. Learn, H. Liao, J. Sodroski, 2016, Proceedings of the National Academy of Sciences.

The Development of CD4 Binding Site Antibodies during HIV-1 Infection

B. Haynes, J. Mascola, R. Dersimonian, 2012, Journal of Virology.

Initial HIV-1 Antigen-Specific CD8+ T Cells in Acute HIV-1 Infection Inhibit Transmitted/Founder Virus Replication

H. Ding, J. Kappes, B. Haynes, 2012, Journal of Virology.

Primary Infection by a Human Immunodeficiency Virus with Atypical Coreceptor Tropism

B. Haynes, R. Doms, F. Gao, 2011, Journal of Virology.

Dynamic Antibody Speciﬁcities and Virion Concentrations in Circulating Immune Complexes in Acute to Chronic HIV-1 Infection (cid:1) †

A. Perelson, J. Kappes, B. Haynes, 2011 .

Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers

H. Liao, B. Haynes, K. Owzar, 2009, AIDS.

Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates

B. Haynes, G. Tomaras, 2013, Vaccines.

Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers

Rachel L. Spreng, Sarah V. Mudrak, T. Hope, 2021, Frontiers in Immunology.

Low-Dose Mucosal Simian Immunodeficiency Virus Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys

B. Haynes, K. Mansfield, N. Letvin, 2010, Journal of Virology.

Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C

Lynn Morris, Michael S. Seaman, John R. Mascola, 2008, Journal of Virology.

CD4+CD8+ T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection

G. Ferrari, G. Tomaras, J. Eron, 2012, The Journal of Immunology.

CD4CD8 T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection

G. Ferrari, G. Tomaras, J. Eron, 2012 .

Acute HIV Infection Portion of the Anti-HIV T Cell Response to T Cells Represent a Significant + CD8+ CD4

G. Ferrari, G. Tomaras, J. Eron, 2012 .

Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection

B. Haynes, G. Ferrari, G. Tomaras, 2017, The Journal of infectious diseases.

Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection

B. Haynes, D. Margolis, G. Ferrari, 2016, Nature Reviews Drug Discovery.

Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.

B. Korber, P. Hraber, H. Liao, 2015, Cell host & microbe.

Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees

Jerome H. Kim, H. Liao, J. Kappes, 2013, Journal of Virology.

HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design.

H. Liao, B. Haynes, L. Verkoczy, 2012, Trends in microbiology.

Differential Reactivity of Germ Line Allelic Variants of a Broadly Neutralizing HIV-1 Antibody to a gp41 Fusion Intermediate Conformation

T. Kepler, H. Liao, B. Haynes, 2011, Journal of Virology.

Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual

Xi Chen, Lynn Morris, Barton F. Haynes, 2011, Journal of Virology.

B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.

H. Liao, B. Haynes, L. Verkoczy, 2011, Trends in molecular medicine.

Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors

Lynn Morris, Peter B. Gilbert, John R. Mascola, 2009, Journal of Virology.

Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection

S. Munir Alam, Susan Zolla-Pazner, Barton F. Haynes, 2007, Journal of Virology.

Human Immunodeﬁciency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection (cid:1)

H. Liao, Laura L. Sutherland, B. Haynes, 2007 .

Antibody responses and virus escape: implications for HIV-1 vaccine and therapeutic design

Xiaoying Shen, G. Tomaras, M. Greenberg, 2006 .

Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection

Gary J. Nabel, Youyi Fong, Peter B. Gilbert, 2014, PloS one.

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Jerome H. Kim, B. Korber, B. Haynes, 2012, AIDS research and human retroviruses.

Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family

Jerome H. Kim, X. Chen, H. Liao, 2012, Journal of Virology.

Direct intranodal tonsil vaccination with modified vaccinia Ankara vaccine protects macaques from highly pathogenic SIVmac251

D. Montefiori, M. Robert-Guroff, O. Onabajo, 2023, Nature Communications.

Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition

D. Montefiori, D. Stablein, D. Venzon, 2016, The Journal of Immunology.

An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum

J. Kappes, B. Haynes, J. Hoxie, 2011, Journal of Virology.

Conformational Epitope Mediates Potent ADCC Activity and Defines a Common 2

J. Kappes, B. Haynes, J. Hoxie, 2011 .

CD8+ T cells: mechanistic target of rapamycin and eukaryotic initiation factor 2 in elite HIV-1 control.

G. Tomaras, Tinashe E. Nyanhete, 2018, AIDS.

Transcriptional and Posttranscriptional Regulation of Cytokine Gene Expression in HIV-1 Antigen-Specific CD8+ T Cells That Mediate Virus Inhibition

G. Ferrari, G. Tomaras, J. Keene, 2014, Journal of Virology.

Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial

Raphael Gottardo, Tomer Hertz, John Sidney, 2014, Journal of Virology.

Secretion of MIP-1β and MIP-1α by CD8(+) T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage.

C. Ward‐Caviness, T. Kepler, R. Schutte, 2011, Cellular immunology.

Epigenetic regulation of CD8(+) T-lymphocyte mediated suppression of HIV-1 replication.

G. Tomaras, K. Saunders, S. Freel, 2010, Virology.

Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination

J. Kappes, B. Haynes, R. Koup, 2010, Journal of Virology.

Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques

H. Liao, Laura L. Sutherland, B. Haynes, 2014, Journal of Virology.

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)

W. Blattner, D. Montefiori, S. Kalams, 2011, PloS one.

Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children

M. Hughes, D. Kuritzkes, M. Lichterfeld, 2022, Journal of acquired immune deficiency syndromes.

Vaccination induces HIV broadly neutralizing antibody precursors in humans

Allan C. deCamp, D. Montefiori, R. Koup, 2022, Science.

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial

Allan C. deCamp, J. Mascola, R. Koup, 2022, Nature Medicine.

CXCL13 is a plasma biomarker of germinal center activity

Mark M. Davis, B. Walker, B. Pulendran, 2016, Proceedings of the National Academy of Sciences.

CD4 T follicular helper cell dynamics during SIV infection.

Michael Y. Gerner, R. Germain, R. Koup, 2012, The Journal of clinical investigation.

Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.

Jerome H. Kim, H. Liao, B. Haynes, 2014, The Journal of infectious diseases.

RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses

Ricardo Henao, C. Woods, G. Ginsburg, 2018, Cell.

Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques.

Jerome H. Kim, H. Liao, Laura L. Sutherland, 2016, JCI insight.

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition

Allan C. deCamp, Jerome H. Kim, S. Zolla-Pazner, 2015, Science Translational Medicine.

Chemical Cross-Linking Neutralization Induced by HIV-1 gp140 Immune Focusing and Enhanced

Q. Sattentau, D. Montefiori, Po-Ssu Huang, 2014 .

Immune Focusing and Enhanced Neutralization Induced by HIV-1 gp140 Chemical Cross-Linking

J. Benschop, Q. Sattentau, D. Montefiori, 2013, Journal of Virology.

Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV

G. Ferrari, Shixia Wang, Shan Lu, 2022, npj Vaccines.

Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV

G. Ferrari, Shixia Wang, Shan Lu, 2022, npj Vaccines.

Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120: Negative Results Fail to Trigger a Phase 3 Correlates Trial

W. Blattner, S. Self, D. Montefiori, 2007, Journal of acquired immune deficiency syndromes.

Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge

J. Weiner, M. Robb, G. Ferrari, 2020, PLoS pathogens.

Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans

Rachel L. Spreng, Sarah V. Mudrak, G. Ferrari, 2022, npj Vaccines.

Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type

D. Montefiori, D. Venzon, G. Alter, 2019, PLoS pathogens.

Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects.

W. Blattner, M. McElrath, N. Russell, 2011, The Journal of infectious diseases.

Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection

Rachel L. Spreng, Sarah V. Mudrak, E. Jongert, 2021, npj Vaccines.

Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.

H. Liao, B. Haynes, J. Fuchs, 2015, Journal of AIDS & clinical research.

The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination

Muhammad Bilal Latif, B. Haynes, R. Koup, 2021, Nature Immunology.

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

M. Nussenzweig, A. West, E. Thomas, 2018, Nature.

IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells

B. Haynes, D. Montefiori, S. Santra, 2018, Communications Biology.

Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

D. Weissman, Laura L. Sutherland, B. Haynes, 2021, NPJ vaccines.

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.

Allan C. deCamp, S. Hammer, J. Mascola, 2019, The Journal of clinical investigation.

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa

J. Kublin, D. Montefiori, M. McElrath, 2019, Science Translational Medicine.

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

Lindsay N. Carpp, Vicki C. Ashley, Allan C. deCamp, 2022 .

Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.

Haiyan Chen, Laura L. Sutherland, B. Haynes, 2017, Cell reports.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Holly Janes, David C Montefiori, Peter B Gilbert, 2013, The New England journal of medicine.

Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design

T. Kepler, X. Chen, H. Liao, 2012, Journal of Virology.

Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41

H. Liao, Laura L. Sutherland, B. Haynes, 2011, PloS one.

A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa

J. Kublin, M. McElrath, A. Fiore-Gartland, 2020, EClinicalMedicine.

Changes in Circulating B Cell Subsets Associated with Aging and Acute SIV Infection in Rhesus Macaques

Xiaoying Shen, G. Tomaras, P. Barry, 2017, PloS one.

Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques

Rachel L. Spreng, T. Hope, M. Tay, 2021, Frontiers in Immunology.

IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria

H. Liao, B. Haynes, Xiao-Jie Yan, 2014, PloS one.

Complex immune correlates of protection in HIV‐1 vaccine efficacy trials

G. Tomaras, Stanley A Plotkin, 2017, Immunological reviews.

High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.

W. Blattner, J. Fuchs, D. Montefiori, 2005, The Journal of infectious diseases.

DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge

N. Sardesai, J. Lifson, D. Venzon, 2013, Proceedings of the National Academy of Sciences.

Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates

R. Steinman, G. Pantaleo, R. Wagner, 2011, Proceedings of the National Academy of Sciences.

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Prima

S. Self, D. Montefiori, R. Gottardo, 2017, Journal of Virology.

Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates

S. Self, D. Montefiori, G. Pantaleo, 2015, Journal of Virology.

Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform

Vicki C. Ashley, Y. Fong, G. Tomaras, 2013, BMC Bioinformatics.

Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform

Linda J. Harris, Youyi Fong, Elizabeth K. Nelson, 2013, BMC Bioinformatics.

HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable

Allan C. deCamp, S. Kalams, M. McElrath, 2011, The Journal of Immunology.

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

W. Blattner, B. Moss, D. Montefiori, 2011, The Journal of infectious diseases.

Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges

J. Weiner, D. Montefiori, G. Alter, 2022, Frontiers in Immunology.

Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants

Allan C. deCamp, W. Blattner, S. Hammer, 2014, Clinical and Vaccine Immunology.

Mucosal Immunization of Lactating Female Rhesus Monkeys with a Transmitted/Founder HIV-1 Envelope Induces Strong Env-Specific IgA Antibody Responses in Breast Milk

Haiyan Chen, H. Liao, B. Haynes, 2013, Journal of Virology.

Progress in HIV-1 vaccine development.

Guido Ferrari, Georgia D Tomaras, Hua-Xin Liao, 2014, The Journal of allergy and clinical immunology.

Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults

B. Korber, B. Haynes, D. Montefiori, 2023, The Journal of clinical investigation.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

S. Hammer, B. Moss, D. Montefiori, 2014, The Journal of infectious diseases.

Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases

D. O’Connor, S. Kleinstein, G. Tomaras, 2021, Vaccine.

Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium

Peter D. Crompton, B. Howie, Bjoern Peters, 2023, Cell Reports.

Aggregate complexes of HIV-1 induced by multimeric antibodies

Jerome H. Kim, B. Haynes, D. Montefiori, 2014, Retrovirology.

CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants

Lindsay N. Carpp, Jerome H. Kim, H. Liao, 2014, PloS one.

Vi-specific serological correlates of protection for typhoid fever

Rachel L. Spreng, Lindsay C. Dahora, B. Gunn, 2020, The Journal of experimental medicine.

AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.

D. Montefiori, S. Buchbinder, M. McElrath, 2021, Vaccine.

RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines

Xiaoying Shen, G. Tomaras, D. Hartigan-O’Connor, 2020, Scientific Reports.

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial

J. Kublin, D. Montefiori, N. Frahm, 2019, The lancet. HIV.

Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates

Xiaoying Shen, G. Tomaras, R. Shattock, 2016, Journal of Virology.

Mechanisms for HIV-1 entry: Current strategies to interfere with this step

G. Tomaras, M. Greenberg, 2001, Current infectious disease reports.

Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response

J. Berzofsky, G. Trinchieri, D. Venzon, 2019, The Journal of clinical investigation.

Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells

Lindsay N. Carpp, M. McElrath, P. Gilbert, 2019, Front. Immunol..

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial

Jerome H. Kim, T. Kepler, H. Liao, 2017, PLoS pathogens.

Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.

David C Montefiori, Georgia D Tomaras, Avishek Nandi, 2010, Virology.

Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans

G. Pantaleo, M. McElrath, P. Gilbert, 2021, NPJ vaccines.

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

S. McCormack, D. Montefiori, R. Gottardo, 2020, PLoS pathogens.

Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge.

B. Haynes, J. Weiner, D. Montefiori, 2020, Cell reports.

Immunological and Virological Mechanisms of Vaccine-Mediated Protection Against SIV and HIV

Mario Roederer, Raphael Gottardo, Gary J. Nabel, 2013, Nature.

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

James Y. Dai, Jerome H. Kim, H. Liao, 2014, The Journal of clinical investigation.

Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials

Raphael Gottardo, Savita Pahwa, William Chad Young, 2021, Frontiers in Big Data.

DNA and Protein Co-Immunization Improves the Magnitude and Longevity of Humoral Immune Responses in Macaques

N. Sardesai, D. Montefiori, J. Lifson, 2014, PloS one.

Changes at V2 apex of HIV-1 Clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies

D. Irvine, D. Montefiori, Kelly K. Lee, 2021, bioRxiv.

Rhesus macaque anti-HIV V3 antibody DH753 with gp120 V3 ZAM18 peptide

B. Korber, B. Haynes, J. Mascola, 2019 .

Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations

B. Korber, B. Haynes, J. Mascola, 2019, Nature Communications.

A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques

B. Moss, D. Montefiori, R. Varadarajan, 2017, Journal of Virology.

Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s

Sarah V. Mudrak, G. Ferrari, M. A. Moody, 2022, Frontiers in Immunology.

Salmonella Typhi Vi capsule prime-boost vaccination induces convergent and functional antibody responses

Lindsay C. Dahora, G. Cavet, S. Alam, 2021, Science Immunology.

Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

D. Weissman, Laura L. Sutherland, B. Haynes, 2021, npj Vaccines.

Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1

T. Hope, D. Montefiori, M. Tay, 2019, Journal of Virology.

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees

Allan C. deCamp, B. Korber, P. Hraber, 2018, Journal of Virology.

Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques

B. Pulendran, B. Moss, D. Montefiori, 2016, Journal of Virology.

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens

Rachel L. Spreng, P. Gilbert, L. Corey, 2020, Scientific Reports.

Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial

Allan C. deCamp, Jerome H. Kim, B. Korber, 2013, PloS one.

Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates.

T. Kepler, B. Korber, E. Go, 2017, Cell reports.

Lower SARS-CoV-2–specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19

O. Hyrien, I. Frank, G. Tomaras, 2022, JCI insight.

Bringing the path toward an HIV-1 vaccine into focus

G. Tomaras, C. L. Lopez Angel, 2020, PLoS pathogens.

Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.

D. Montefiori, I. Frank, G. Ferrari, 2023, Vaccine.

HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis

Jerome H. Kim, H. Liao, B. Haynes, 2018, Journal of Virology.

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults

D. Montefiori, S. Buchbinder, N. Frahm, 2017, PloS one.

HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities

H. Liao, B. Haynes, M. McElrath, 2014, PloS one.

Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide

Jerome H. Kim, H. Liao, B. Haynes, 2014, Journal of Virology.

Capacity for Infectious HIV-1 Virion Capture Differs by Envelope Antibody Specificity

H. Liao, B. Haynes, T. Hope, 2014, Journal of Virology.

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

D. Montefiori, M. McElrath, L. Corey, 2011, The Journal of infectious diseases.

COMPASS identifies T-cell subsets correlated with clinical outcomes

Greg Finak, Raphael Gottardo, Jaranit Kaewkungwal, 2015, Nature Biotechnology.

Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell‐mediated cytotoxicity assay

Y. Hu, R. Koup, G. Ferrari, 2018, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities

Jerome H. Kim, H. Liao, B. Haynes, 2014, Journal of Virology.

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.

Jerome H. Kim, P. Zhang, E. Go, 2020, JCI insight.

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency

Jerome H. Kim, T. Kepler, B. Haynes, 2019, Journal of Virology.

Immune correlates of vaccine protection against HIV-1 acquisition

B. Haynes, A. Fauci, G. Pantaleo, 2015, Science Translational Medicine.

Lack of B Cell Dysfunction Is Associated with Functional, gp120-Dominant Antibody Responses in Breast Milk of Simian Immunodeficiency Virus-Infected African Green Monkeys

H. Liao, D. Montefiori, M. A. Moody, 2013, Journal of Virology.

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

S. Self, D. Montefiori, R. Gottardo, 2016, Journal of Virology.

Title Employing Improved Antigens Allows Streamlining of Heterologous DNA-Prime and NYVAC / Protein-Boost HIV Vaccine Regimens in Rhesus Macaques Running title : Improved HIV Antigens and Delivery Schedules in Macaques

Ralf, Barnett, D. Montefiori, 2015 .

HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.

H. Liao, B. Haynes, D. Montefiori, 2014, The Journal of clinical investigation.

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection

D. Montefiori, L. Morris, P. Gilbert, 2020, mSphere.

Methods for comparing durability of immune responses between vaccine regimens in early-phase trials

T. Westling, P. Gilbert, G. Tomaras, 2019, Statistical methods in medical research.

Strategies for eliciting HIV-1 inhibitory antibodies

B. Haynes, G. Tomaras, 2010, Current opinion in HIV and AIDS.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA

R. Gottardo, N. Frahm, Greg Finak, 2017, Clinical and Vaccine Immunology.

High-density binding to Plasmodium falciparum circumsporozoite protein repeats by inhibitory antibody elicited in mouse with human immunoglobulin repertoire

H. Wardemann, J. Rubinstein, P. Kellam, 2022, PLoS pathogens.

Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIVmac251 Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial

Jerome H. Kim, D. Montefiori, D. Stablein, 2012, Journal of Virology.

Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge

B. Keele, M. Roederer, G. Tomaras, 2011, Mucosal Immunology.

Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques

H. Liao, B. Haynes, D. Montefiori, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial

D. Montefiori, R. Gottardo, G. Ferrari, 2021, Vaccine.

Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion

Jerome H. Kim, Haiyan Chen, H. Liao, 2012, Journal of Virology.

Cholera toxin B scaffolded, focused SIV V2 epitope elicits antibodies that influence the risk of SIVmac251 acquisition in macaques

R. Veazey, C. Labranche, Y. Patskovsky, 2023, Frontiers in Immunology.

Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant

Jerome H. Kim, H. Liao, B. Haynes, 2018, PloS one.

A tool for evaluating heterogeneity in avidity of polyclonal antibodies

Rachel L. Spreng, Lindsay C. Dahora, E. Jongert, 2023, Frontiers in Immunology.

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial

D. Montefiori, G. Pantaleo, M. McElrath, 2019, The Journal of clinical investigation.

Broadly Reactive Monoclonal Antibodies to Multiple HIV-1 Subtype and SIVcpz Envelope Glycoproteins

B. Korber, H. Liao, B. Haynes, 2009 .

Reversible Reprogramming of Circulating Memory T Follicular Helper Cell Function during Chronic HIV Infection

S. Migueles, M. Connors, R. Koup, 2015, The Journal of Immunology.

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein

Allan C. deCamp, J. Kublin, S. Omarjee, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The quest for vaccine-induced immune correlates of protection against tuberculosis

N. Frahm, M. McElrath, O. Hyrien, 2022, Vaccine insights.

CD8+ T cell mediated noncytolytic inhibition of human immunodeficiency virus type I.

G. Tomaras, M. Greenberg, 2001, Frontiers in bioscience : a journal and virtual library.

CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus (SIV) Vaccine Enhances Protection against Neutralization-Resistant Mucosal SIV Infection

B. Moss, D. Montefiori, C. Labranche, 2015, Journal of Virology.

HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge

B. Moss, D. Montefiori, R. Varadarajan, 2019, Nature Communications.

Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV

D. Lauffenburger, B. Haynes, J. Weiner, 2018, Nature Medicine.

Improving peptide-MHC class I binding prediction for unbalanced datasets

Ana Paula Sales, Thomas B. Kepler, Georgia D. Tomaras, 2008, BMC Bioinformatics.

Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.

Rachel L. Spreng, Lindsay C. Dahora, Jerome H. Kim, 2023, PLoS pathogens.

Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance.

T. Wrin, G. Ferrari, G. Tomaras, 2005, AIDS research and human retroviruses.

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine

B. Haynes, B. Moss, D. Montefiori, 2017, Journal of Virology.

Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization

D. Montefiori, G. Ferrari, Shiu-Lok Hu, 2016, Journal of Virology.

Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice

B. Haynes, L. Macdonald, A. Murphy, 2017, The Journal of Immunology.

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants

J. Andriesen, Yunda Huang, G. Tomaras, 2023, PLOS global public health.

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study

J. Kublin, D. Montefiori, H. Schuitemaker, 2022, The Journal of infectious diseases.

Author Correction: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

D. Weissman, Laura L. Sutherland, B. Haynes, 2020, npj Vaccines.

Robust antibody and cellular responses induced by DNA-only vaccination for HIV.

N. Sardesai, D. Weiner, Jian Yan, 2020, JCI insight.

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

J. Kublin, D. Montefiori, N. Frahm, 2020, PLoS medicine.

Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination.

E. Jongert, M. Debois, G. Tomaras, 2020, Vaccine.

Galactosylceramide the Interaction of HIV-1 gp 140 with Expose a CD 4-Inducible Epitope and Block Constant Region 1-Specific Antibodies Vaccine-Induced HIV-1 Envelope gp

Jerome H. Kim, H. Liao, B. Haynes, 2014 .

Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1

H. Liao, B. Haynes, S. Rerks-Ngarm, 2017, Journal of Virology.

Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS

G. Tomaras, D. Barouch, N. Yates, 2021, Frontiers in Immunology.

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk

Lindsay N. Carpp, J. Kublin, M. McElrath, 2021, PLoS pathogens.

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine

Jerome H. Kim, R. Gottardo, R. Koup, 2019, Nature Communications.

Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.

Xuesong Yu, David C Montefiori, Georgia D Tomaras, 2015, Vaccine.

H3N2 Influenza Infection Elicits More Cross-Reactive and Less Clonally Expanded Anti-Hemagglutinin Antibodies Than Influenza Vaccination

T. Kepler, X. Chen, C. Woods, 2011, PloS one.

Lessons From a Multisite International Trial in the Caribbean and South America of an HIV-1 Canarypox Vaccine (ALVAC-HIV vCP1452) With or Without Boosting With MN rgp120

D. Montefiori, S. Gurunathan, D. Lawrence, 2007, Journal of acquired immune deficiency syndromes.

Spectrum of HIV antibodies in vaccine and disease.

D. Montefiori, G. Tomaras, 2014, Current opinion in HIV and AIDS.

Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.

A. Folgori, D. Montefiori, C. Labranche, 2016, Vaccine.

HIV-DNA Priming Alters T Cell Responses

Allan C. deCamp, S. Kalams, M. McElrath, 2011 .

Tailoring Tfh Profiles Enhances Antibody Persistence to a Clade C HIV-1 Vaccine in Rhesus Macaques

D. Rajasundaram, G. Tomaras, R. Amara, 2023, bioRxiv.

Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection

H. Liao, Laura L. Sutherland, B. Haynes, 2016, EBioMedicine.

Initiation of Human Immunodeficiency Virus Type 1 (HIV-1) Transcription is Inhibited by Noncytolytic CD8+ Suppression

M. Garcia-Blanco, G. Tomaras, M. Greenberg, 2007, The open virology journal.

Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization.

J. Murray, J. Trent, G. Tomaras, 2000, Journal of molecular biology.

TitrationAnalysis: a tool for high throughput binding kinetics data analysis for multiple label-free platforms

S. Dennison, G. Tomaras, Gillian Q. Horn, 2023, Gates Open Research.

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

Allan C. deCamp, J. Mullins, J. Weiner, 2023, EBioMedicine.

Proceedings of the Frontiers of Retrovirology Conference 2016

Sebastian A. Wagner, R. König, D. Elleder, 2016, Retrovirology.

Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector

D. Montefiori, R. Gottardo, G. Pantaleo, 2019, Scientific Reports.

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.

Allan C. deCamp, J. Kublin, S. Buchbinder, 2016, Current opinion in virology.

Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

M. Nussenzweig, N. Pfeifer, S. Scholten, 2018, Nature Medicine.

Coronavirus Immunotherapeutic Consortium Database

James A. Overton, J. Greenbaum, Bjoern Peters, 2023, Database J. Biol. Databases Curation.

Magnitude, Specificity, and Avidity of Sporozoite-Specific Antibodies Associate With Protection Status and Distinguish Among RTS,S/AS01 Dose Regimens

Rachel L. Spreng, E. Jongert, S. Alam, 2020, Open Forum Infectious Diseases.

Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques

D. Montefiori, M. Ostrowski, R. Koup, 2020, Journal of Virology.

Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions

B. Haynes, R. Baric, G. Ferrari, 2023, bioRxiv.

Response to Comment on “CD4+CD8+ T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection”

G. Ferrari, G. Tomaras, M. Frahm, 2012, The Journal of Immunology.

Restricted isotype, distinct variable gene usage, and high rate of gp120-specificity of HIV-1 Envelope-specific B cells in colostrum compared to those in blood of HIV-1-infected, lactating African women

T. Kepler, H. Liao, B. Haynes, 2014, Mucosal Immunology.

Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques

D. Montefiori, J. Heeney, G. Ferrari, 2017, Journal of Virology.

Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations

B. Korber, B. Haynes, J. Mascola, 2019, Nature Communications.

Rectal and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge

M. McElrath, A. McDermott, J. Ledgerwood, 2021 .

Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel

D. Lauffenburger, M. Altfeld, L. Morris, 2015, Mucosal Immunology.

HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge

B. Moss, D. Montefiori, R. Varadarajan, 2019, Nature Communications.

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

James Y. Dai, Jerome H. Kim, B. Haynes, 2014, The Journal of clinical investigation.

D. Montefiori, S. Buchbinder, N. Frahm, 2017, PloS one.

Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies

T. Kepler, S. Hammer, B. Haynes, 2015, Science.

Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates

B. Korber, Laura L. Sutherland, B. Haynes, 2018, Journal of Virology.

HIV Research for Prevention 2018: From Research to Impact Conference Summary and Highlights

S. Buchbinder, C. Herrera, N. Mgodi, 2019, AIDS research and human retroviruses.

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

Lindsay N. Carpp, Vicki C. Ashley, Allan C. deCamp, 2018, The Journal of infectious diseases.

Novel directions in HIV-1 vaccines revealed from clinical trials.

N. Russell, G. Tomaras, J. Excler, 2013, Current opinion in HIV and AIDS.

HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers

B. Haynes, William J. Faison, M. A. Moody, 2019, Scientific Reports.

The Landscape of Targeted Immune Responses in the HIV-1 Vaccine Field

Allan C. deCamp, J. Safrit, G. Tomaras, 2016, AIDS research and human retroviruses.

Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques

B. Haynes, D. Montefiori, S. Santra, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Vectors Prime for Strong Cellular Responses to Simian Immunodeficiency Virus Gag in Rhesus Macaques

B. Haynes, John P. Miller, W. Jacobs, 2014, Clinical and Vaccine Immunology.

Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection

Allan C. deCamp, S. Zolla-Pazner, D. Montefiori, 2014, PloS one.

High‐throughput quantitative analysis of HIV‐1 and SIV‐specific ADCC‐mediating antibody responses

J. Kappes, B. Haynes, J. Hoxie, 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

J. Kappes, B. Haynes, J. Hoxie, 2011, Journal of Virology.

Recombinant Bacillus Calmette-Guérin vectors prime for strong cellular responses

B. Haynes, John P. Miller, M. Lifton, 2014 .

CD4+CD8+ T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection

G. Tomaras, J. Eron, C. Hicks, 2012, Journal of Immunology.

Kernel-based logistic regression model for protein sequence without vectorialization.

I. Georgiev, P. Kwong, Y. Fong, 2015, Biostatistics.

Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design

T. Kepler, X. Chen, B. Haynes, 2012, Journal of Virology.

Defining genetic diversity of rhesus macaque Fcγ receptors with long-read RNA sequencing

M. A. Moody, K. Wiehe, M. Pazgier, 2024, Frontiers in Immunology.

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

Allan C. deCamp, J. Mullins, J. Weiner, 2023, EBioMedicine.

Four-parameter paired response curve for serial dilution assays

Y. Fong, G. Tomaras, S. Permar, 2021, Journal of biopharmaceutical statistics.

Is developing an HIV-1 vaccine possible?

B. Haynes, G. Tomaras, H. Liao, 2010, Current opinion in HIV and AIDS.

H3N2 Influenza Infection Elicits More Cross-Reactive and Less Clonally Expanded Anti-Hemagglutinin Antibodies Than Influenza Vaccination

T. Kepler, X. Chen, C. Woods, 2011, PloS one.

Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1

G. Fouda, G. Tomaras, D. Jamieson, 2015, Journal of Virology.

Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual

X. Chen, B. Haynes, J. Whitesides, 2011, Journal of Virology.

Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial

Allan C. deCamp, N. Frahm, A. Fiore-Gartland, 2024, EBioMedicine.